Trial Profile

Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elexacaftor/ivacaftor/tezacaftor (Primary) ; Ivacaftor (Primary) ; Ivacaftor/tezacaftor (Primary)
Indications Cystic fibrosis
Focus Therapeutic Use

Most Recent Events

16 Apr 2025 Status changed from completed to discontinued. Reason the study was stopped: summary results revealed ineffective intervention and the trial was terminated prematurely. No formal statistical analysis was performed.
13 Dec 2024 Status changed from recruiting to completed.
06 Dec 2023 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com